Combination of Ibrutinib and Bortezomib Followed by Ibrutinib Maintenance to Treat Patients With Relapsed and Refractory Mantle Cell Lymphoma; a Multicenter Phase I/II Trial.
Phase of Trial: Phase I/II
Latest Information Update: 25 Nov 2017
At a glance
- Drugs Bortezomib (Primary) ; Ibrutinib (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 03 Mar 2017 Planned End Date changed from 1 Mar 2021 to 1 Dec 2021.
- 03 Mar 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.
- 17 Aug 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.